Companies
Amgen
Biotech pioneer founded 1980 — Enbrel, Prolia, and PCSK9 inhibitor Repatha; large-scale CHO cell culture manufacturing at Thousand Oaks and Puerto Rico sites.
- Country
- United States
- Revenue
- $33.4B
- Employees
- ~24,000 emp
FDA GMP
GMP EU
Coverage
| CN | EU | US | |
|---|---|---|---|
| therapeutics-platforms | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Headquarters | Thousand Oaks, California | amgen.com · wwwext.amgen.com |
| Headcount | approximately 31,500 worldwide | amgen.com · wwwext.amgen.com |
| Revenue | $36.8 billion (2025) | amgen.com · wwwext.amgen.com |
| Production site | United States (including Puerto Rico, Rhode Island, Ohio, California), Ireland, Netherlands, and Singapore | investors.amgen.com |
| Capacity | Expanding and optimizing network with state-of-the-art facilities; Juncos (Puerto Rico) is one of the world's largest; Ohio and North Carolina facilities added recently | investors.amgen.com · amgen.com |
| Regulatory approval | Products including Enbrel, Prolia, and Repatha have received FDA and international regulatory approvals | investors.amgen.com · amgen.com · fiercepharma.com |
Independent sources: fiercepharma.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Biologics | therapeutics-platforms | Low | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.